New mpox strain confirmed in US state for first time
The New York State Department of Health issued a health advisory Wednesday about the emergence of a new strain of mpox (formerly monkeypox).
The first case of mpox clade Ib in New York State was confirmed in a symptomatic individual who had recently traveled from Africa.
The present risk to the public remains low, the department noted, and there are no additional known community cases of this strain in New York State currently.
State Health Commissioner Dr. James McDonald shared that the infected individual is under the care of a physician and isolated "until the full resolution of symptoms."
"There is no known local transmission of mpox clade Ib in the community where the individual lives or anywhere within New York State," he said in a statement.
McDonald added that the JYNNEOS vaccine, which is a two-dose preventative vaccine series for mpox, is "expected to be effective" against this new strain.
"[It is] available for individuals at risk with the standing order I signed last year," he noted. "There is no immediate risk to the general public."
For more Health articles, visit www.foxnews.com/health
The health department added in its advisory that individuals should inquire with their local pharmacy or healthcare provider about vaccine availability as they continue to "monitor and maintain the situation."
Mpox is "rarely fatal," according to the department, but can be dangerous for people with immunocompromising conditions, as well as older adults, young children and pregnant women.
Symptoms can include rashes that progress to "painful skin lesions," in addition to swollen lymph nodes, fever, sore throat, headaches, back pain, low energy and muscle aches, the department listed.
There is a "high likelihood of transmission" until these lesions scab over, which means infected individuals are encouraged to isolate until new skin forms at the lesion site.
"There is no immediate risk to the general public."
Mpox can spread through close, intimate contact with sores, scabs or rashes, the department stated, as well as through the respiratory droplets, saliva or mucus of an infected person.
Those who plan to travel to areas with reported cases of mpox should consider being vaccinated with the two doses of JYNNEOS, experts recommend.
Dr. Myles Druckman, global medical director at International SOS in California, told Fox News Digital that there have been reports of this strain in several countries in Central and Eastern Africa.
"We're finding that other countries have also reported travel-associated cases of clade I, including Belgium, Canada, China, France, Germany, India, Ireland, Oman, Pakistan, South Sudan, Sweden, Thailand, the United Kingdom and Zimbabwe," he noted.
"Cases of this strain are expected due to the ongoing outbreak in multiple countries and the risks associated with global travel."
"It's important to recognize that cases of this strain are expected due to the ongoing outbreak in multiple countries and the risks associated with global travel."
Mpox can be infectious for up to four days before symptoms occur, but it is most contagious from the time symptoms appear until about two to four weeks later, according to Druckman.
The expert emphasized that vaccination is recommended for high-risk individuals, such as healthcare workers with high exposure or people with weakened immune systems.
"Prevention of mpox is mainly through vaccination and avoiding skin-to-skin contact with others – especially those with symptoms or visible outbreaks – and observing good personal hygiene and washing hands well and frequently," he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Wildfire smoke from Canada prompts air quality health advisory
NEW YORK (WWTI) – New York DEC Commissioner Amanda Lefton and DOH Commissioner Dr. James McDonald are issuing an Air Quality Health Advisory for fine particulate matter on June 7, 2025, due to wildfire smoke from Canada. Air quality alert issued for much of New York State The pollutant of concern is: Fine Particulate Matter The advisory will be in effect 10 a.m. through 11:59 p.m. The Air Quality Health Advisory regions consist of: Adirondacks, which includes Clinton, Essex, Franklin, Hamilton, northern Herkimer, Lewis, St. Lawrence, and Warren counties; Eastern Lake Ontario, which includes northern Cayuga, Jefferson, Monroe, Oswego, and Wayne counties; Central New York, which includes Allegany, Broome, southern Cayuga, Chemung, Chenango, Cortland, Delaware, southern Herkimer, Livingston, Madison, Onondaga, Oneida, Ontario, Otsego, Tioga, Tompkins, Schuyler, Seneca, Steuben, and Yates, and Western New York, which includes Cattaraugus, Chautauqua, Erie, Genesee, Niagara, Orleans, and Wyoming counties. DEC and DOH issue Air Quality Health Advisories when pollution levels, like ozone or PM2.5, are expected to exceed an AQI value of 100, indicating health risks. Fine particulate matter (PM 2.5) consists of tiny particles or droplets in the air, measuring 2.5 microns or less. These particles can come from combustion sources like vehicle exhaust, power plants and fires, as well as chemical reactions in the atmosphere. Exposure to PM 2.5 can lead to short-term health issues such as eye, nose and throat irritation, coughing, sneezing, and shortness of breath. It may also worsen conditions like asthma and heart disease, particularly affecting sensitive groups like those with heart or breathing problems, children, and the elderly. To reduce exposure during elevated outdoor levels, staying indoors can help, although indoor sources like tobacco or cooking fumes can still keep levels high. Recommendations include minimizing sources of PM 2.5 and avoiding strenuous activities in polluted areas. More information is available on DEC's and DOH's websites. Bongino, Patel defend ICE amid unrest over Los Angeles raids Ohio girl with brain injury from flu complications returns home Simone Biles rails against 'sore loser' conservative activist over trans athletes Protesters confront immigration agents, deputies during raid in Los Angeles County Streaming services next steps: What are Mubi, Tubi, and more? Additional information on PM 2.5 is available on DEC's website and on DOH's website (PM 2.5). A new DEC fact sheet about the Air Quality Index is also available on DEC's website or by PDF download. To stay up-to-date with announcements from DEC, sign up to receive Air Quality Alerts through DEC Delivers: DEC's Premier Email Service. A toll-free Air Quality Hotline (1-800-535-1345) was also established by DEC to keep New Yorkers informed of the latest air quality situation Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
Yahoo
2 days ago
- Yahoo
Common menopause medication might prevent breast cancer while treating hot flashes
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, "significantly reduced" breast tissue cell growth, which is a major indicator of cancer progression. A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. Prostate Cancer Drug Now Available To More Patients With Aggressive Form Of Disease This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Read On The Fox News App Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. "The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo," Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. Experimental Women's Cancer Drug Boosts Survival Rates In Notable Study Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. "This would be expected, as the drug is FDA-approved to treat hot flashes." Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings are preliminary and have not yet been published in a medical journal. "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced "high-risk lesions" — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. "These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options," the release stated. The researchers said they are "encouraged" by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. "Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure," Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. "While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk," she told Fox News Digital. Click Here To Sign Up For Our Health Newsletter Kabraji also noted that the study focused on reducing levels of one specific protein, "which does not always predict reduced recurrence of breast cancer." "This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer," she noted. "Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention." For more Health articles, visit Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. "Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms," she article source: Common menopause medication might prevent breast cancer while treating hot flashes
